Abstract: A filling apparatus for, a filling system for and a method of introducing into a container a suspension or solution of a substance, in particular a pharmaceutical substance, in a propellant under pressure, the filling apparatus comprising: a main body (4) including a passageway (20) for communicating, in use, with a valve stem (144) extending from a head (141) of a body (139) of a container (138); a fill actuator (7) comprising a filling valve assembly (29) in communication with the passageway (20) for selectively introducing thereinto propellant under pressure containing a substance in a suspension or solution; an exhaust actuator (10) comprising an exhaust valve assembly (48) in communication with the passageway (20) for selectively exhausting therefrom propellant under pressure containing substance; and a container-engaging body (16) in communication with the passageway (20) for receiving, in use, the head (141) of the body (139) of the container (138), the container-engaging body (16) including a chamber

Abstract: An actuator for an inhaler for administering medicament by inhalation, comprising: a main body (102) comprising an elongate tubular member (108) for receiving a canister (107) containing medicament and having a valve stem (111) extending therefrom, the tubular member (108) including a lateral opening (114) at one end thereof; and an outlet assembly (104) comprising a mouthpiece for guiding medicament to the mouth of a user and a nozzle block (120) for receiving the valve stem (111) of the canister (107) and delivering medicament from the canister (107) into the mouthpiece, the outlet assembly (104) being detachably mounted, through the lateral opening (114), to the main body (102) at an angle transverse to the length of the tubular member (108); characterized in that one of the main body (102) and the outlet assembly (104) further comprises at least one resiliently biased member, which is configured to engage with at least one part of the other of the main body (102) and the outlet assembly (104) and thereby

Abstract: A filling apparatus for, a filling system for and a method of introducing into a container a suspension or solution of a substance, in particular a pharmaceutical substance, in a propellant under pressure, the filling apparatus comprising: a main body (4) including a passageway (20) for communicating, in use, with a valve stem (144) extending from a head (141) of a body (139) of a container (138); a fill actuator (7) comprising a filling valve assembly (29) in communication with the passageway (20) for selectively introducing thereinto propellant under pressure containing a substance in a suspension or solution; an exhaust actuator (10) comprising an exhaust valve assembly (48) in communication with the passageway (20) for selectively exhausting therefrom propellant under pressure containing substance; and a container-engaging body (16) in communication with the passageway (20) for receiving, in use, the head (141) of the body (139) of the container (138), the container-engaging body (16) including a chamber

Abstract: The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.

Abstract: There are provided novel compounds of formula (I) ##STR1## wherein A represents a benzo ring; a six membered heterocyclic aromatic ring containing 1 to 3 nitrogen atoms; or a five membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S; and R.sup.1, R.sup.2, R.sup.3 and X are as defined in the Specification and pharmaceutically acceptable salts thereof and enantiomers and tautomers thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment and prophylaxis of inflammatory disease and pain.

Abstract: There are provided novel compounds of formula (I) ##STR1## wherein A represents an aromatic carbocyclic ring or a 5- or 6-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S; X represents --(CH.sub.2).sub.n -- wherein n represents zero or 1; and R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and tautomers thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

Abstract: A compound of formula I, including optical isomers thereof, whereinX represents --SO.sub.2 NH-- or --NHSO.sub.

Abstract: This invention relates to an improved process for the production of known amine compounds which are useful as medicaments.

Abstract: The invention provides certain novel 5-substituted pyrrolo[3,4-d]pyrimidine-2,4-diones, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and methods of treatment involving their use.

Abstract: There are disclosed compounds of formula I, ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen or halogen, R.sup.3 and R.sup.4 independently represent phenyl, or alkyl C.sub.1-6 optionally substituted by one or more substituents selected from OR.sup.5, alkylthio C.sub.1-6, NR.sup.6 R.sup.7, phenyl, COOR.sup.8 and halogen,R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen or alkyl C.sub.1-6, andX represents an acidic moiety,and pharmaceutically acceptable salts thereof. Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.

Abstract: Compounds of formula I, ##STR1## wherein X represents naphthyl optionally substituted by alkyl or halogen; andp, q and r independently represent 2 or 3,and pharmaceutically acceptable salts thereof;processes for their preparation and methods for their use.

Abstract: Compounds of formula (I) wherein: R.sup.1 and R.sup.19 independently represent hydrogen, alkyl C1-6, alkoxy C1-6, alkylthio C1-6, halogen, hydroxyl or amino;R.sup.2 represents H or alkyl;R.sup.3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O,N, and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1-6, alkoxy C1-6, haologen, hydroxyl, alkylthio C1-6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group --(CH.sub.2).sub.c NHCO.sub.2 R.sup.10, a group --(CH.sub.2).sub.c NR.sup.5 R.sup.6, or a group --CO.sub.2 R.sup.11 ; or R.sup.3 represents hydrogen or alkyl C1-8, which alkyl group may be optionally substituted by amino or a group --NHCO.sub.2 R.sup.10 ;R.sup.4 represents hydrogen or alkyl C1-6; orR.sup.3 and R.sup.4 taken together represent a group (CH.sub.2).sub.a Z(CH.sub.2).sub.

Abstract: A compound of formula I, including optical isomers thereof, ##STR1## wherein X represents --SO.sub.2 NH-- or --NHSO.sub.2 --,p, q and r independently represent 2 or 3,Y represents thienyl optionally substituted by alkyl or halogen, or phenylthio- or phenyl optionally substituted by alkyl or halogen, andeach R independently represents H or alkyl,and pharmaceutically acceptable salts, esters and amides thereof.

Abstract: There are disclosed compounds of formula I,Ar--CH.sub.2 CH.sub.2 --NH--CR.sup.1 R.sup.2 --X--Y Iin whichAr represents a group, ##STR1## X represents a C.sub.1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from --S(O).sub.n --, --O--, --C(Z)--, CR.sup.6 R.sup.7, phenylmethyne, --NR.sup.8 --, --CONH--, --NHCO-- and --NHCONH--,Y represents an optionally substituted aryl or cycloalkyl group,Z represents O or S,R.sup.1, R.sup.2, R.sup.5 and R.sup.9 each independently represent hydrogen or alkyl C.sub.1-6,R.sup.3 and R.sup.4 represent hydrogen, or R.sup.3 and R.sup.4 together form a group --S--, --NR.sup.9 -- or --CH.sub.2 --,R.sup.6 and R.sup.7 independently represent hydrogen, alkyl C.sub.1-6, fluoro, cyano, or CF.sub.3, provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen,R.sup.8 represents hydrogen or alkyl C.sub.1-6, or when X is interrupted or terminated by more than one --NR.sup.8 -- group may together with another R.sup.8 group form the chain --CH.

Abstract: Compounds of the formula (I) ##STR1## wherein B is O or CH.sub.2 ;X is selected from NR.sup.1 R.sup.2, SR.sup.1, and C.sub.1 -C.sub.7 alkyl;Y is selected SR.sup.1, NR.sup.1 R.sup.2, and C.sub.1 -C.sub.7 alkyl;R.sup.1 and R.sup.2 is each and independently selected from H, or C.sub.1 -C.sub.7 alkyl optionally substituted upon or within the alkyl chain by one or more of O, S, N or halogen;R.sup.3 and R.sup.4 are both H, or R.sup.3 and R.sup.4 together form a bond;A is COOH, C(O)NH(CH.sub.2).sub.p COOH, C(O)N?(CH.sub.2).sub.q COOH!.sub.2, C(O)NHCH(COOH)(CH.sub.2).sub.r COOH, or 5-tetrazolyl, wherein p, q and r is each and independently 1, 2 or 3;as well as pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions comprising the novel compounds and use of the compounds in therapy. Also within the scope of the invention are novel intermediates to the novel compounds. The novel compounds are in particular useful in the prevention of platelet aggregation.

Abstract: There are disclosed compounds of formula I, ##STR1## wherein Q represents CR.sup.1 R.sup.2,R represents O or CR.sup.3 R.sup.4,W represents O or CH.sub.2,R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen or halogen,X represents S(O).sub.n R.sup.5, alkyl C.sub.1-6 alkoxy C.sub.1-6, acylamino C.sub.1-6, CONR.sup.6 R.sup.7, NR.sup.8 R.sup.9, halogen, a 5- or 6-membered S containing heterocycle, or phenyl optionally substituted by alkyl C.sub.1-6,n represents 0, 1 or 2,R.sup.5 represents aryl or alkyl C.sub.1-6 optionally substituted by one or more substituents selected from hydroxy, alkoxy C.sub.1-6, halogen and aryl;R.sup.6, R.sup.7, R.sup.8 and R.sup.9 independently represent hydrogen or alkyl C.sub.1-6,Y represents NH.sub.2 or alkoxy C.sub.1-6, andZ represents an acidic moiety,in addition, when R represents CR.sup.3 R.sup.4, then --Q--Z may also represent hydroxy or --OP(O)(OH).sub.2,and pharmaceutically acceptable salts thereof, with certain provisos, for use as pharmaceuticals.

Abstract: There are disclosed compounds of formula I,Ar--CH.sub.2 CH.sub.2 --NH--CR.sup.1 R.sup.2 --X--Y Iin whichAr represents a group, ##STR1## X represents a C.sub.1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from --S(O).sub.n --, --O--, --C(Z)--, CR.sup.6 R.sup.7, phenylmethyne, --NR.sup.8 --, --CONH--, --NHCO-- and --NHCONH--,Y represents an optionally substituted aryl or cycloalkyl group,Z represents O or S,R.sup.1, R.sup.2, R.sup.5 and R.sup.9 each independently represent hydrogen or alkyl C.sub.1-6,R.sup.3 and R.sup.4 represent hydrogen, or R.sup.3 and R.sup.4 together form a group --S--, --NR.sup.9 -- or --CH.sub.2 --,R.sup.6 and R.sup.7 independently represent hydrogen, alkyl C.sub.1-6, fluoro, cyano, or CF.sub.3, provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen,R.sup.8 represents hydrogen or alkyl C.sub.1-6, or when X is interrupted or terminated by more than one --NR.sup.8 -- group may together with another R.sup.8 group form the chain --CH.